11/16/20 11:22 PMNasdaq : GHGuardant Health, Inc. Prices $1 Billion Convertible Senior Notes OfferingGuardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due 2027 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The issuance and sale of the notes are scheduled to settle on November 19, 2020, subject to customary closing conditions. Guardant HealRHEA-AIneutral
11/16/20 6:47 AMNasdaq : GHGuardant Health, Inc. Announces Proposed Convertible Senior Notes OfferingGuardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Guardant Health also expects to grant the initial purchasers of the notes an option to purchase, for settRHEA-AIneutral
11/05/20 4:03 PMNasdaq : GHGuardant Health Reports Third Quarter 2020 Financial ResultsGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Recent Highlights Revenue of $74.6 million for the third quarter of 2020, an increase of 23% over the corresponding period of 2019 Precision oncology revenue of $60.4 million, an increasRHEA-AIneutral
10/16/20 4:05 PMNasdaq : GHGuardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available foRHEA-AIneutral
10/15/20 4:05 PMNasdaq : GHGuardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling StockholderGuardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the closings of an underwritten public offering of 7,700,000 shares of its common stock, which includes full exercise of the underwriter's option to purchase 700,000 shares, at a public offering price of $102.00 per share, beRHEA-AIneutral
10/07/20 9:06 AMNasdaq : GHGuardant Health Announces Pricing of Public Offering of Common Stock by Selling StockholderGuardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the pricing of an underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $102.00 per share, before deducting underwriting discounts and commissions, all of which are being sold by SRHEA-AIneutral
10/06/20 4:54 PMNasdaq : GHGuardant Health Announces Proposed Public Offering of Common Stock by Selling StockholderGuardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the commencement of a proposed underwritten public offering of 7,000,000 shares of its common stock being offered for sale by SoftBank Investment Advisers. In addition, SoftBank Investment Advisers expects to grant the underwRHEA-AIneutral
10/05/20 4:05 PMNasdaq : GHLarge-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue BiopsyGuardant Health, Inc. (Nasdaq: GH). Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360(R) liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detectRHEA-AIpositive
09/01/20 4:03 PMNasdaq : GHGuardant Health to Participate in Morgan Stanley 2020 Healthcare ConferenceGuardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference. Guardant Health's management is scheduled for a fireside chat on Tuesday, September 15 atRHEA-AIneutral
08/10/20 8:05 AMNasdaq : GHGuardant Health to Participate in Upcoming August Investor ConferencesGuardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the following investor virtualRHEA-AIneutral
